Cohort Company News

The OneRNA4Bladder project aims to save lives and halve the cost of care for bladder-cancer treatment. Bladder cancer is the most expensive cancer to treat due to expensive diagnostic procedures and ineffective drugs resulting in a recurrence rate of 70%.

Medical care is no longer confined to the doctor’s office. Or even, sometimes, to an actual doctor. That iPhone in your pocket now has the capability to diagnose your cough, answer insurance questions, and get you pregnant…or at least help the process along.

Some medical technologies can require hundreds of uses before a surgeon becomes proficient with them. Typical surgeon training involves working with cadavers, but doing this only allows trainees one, maybe two, sessions' worth of experience.

For an octogenarian with arthritic knees, a voice-controlled light switch could ease the pain of having to stand and walk just to illuminate a room. For a nonagenarian, a robot that offers brain-teasing games to help keep her mind sharp could become an ideal companion.

We haven’t even come close to solving the problem of an aging population, so the tech sector is stepping in. Just this week, in Boston, six nursing homes announced plans to close without explanation.

AUM Cardiovascular has been named a gold winner in Best New Product of the Year – Healthcare in Best in Biz Awards, the only independent business awards program judged each year by prominent editors and reporters from top-tier publications in North America.

San Francisco-based patient engagement startup Catalia Health has announced an additional $4 million in pre-Series A funding from Ion Pacific and other investors.

Vyaire Medical, Inc., the healthcare industry’s dedicated “breathing company,” today announced it has acquired Revolutionary Medical Devices, Inc. (RMD), of Tucson, Ariz., a maker of innovative products for airway management, focused on significantly improving patient outcomes.

In the joint research project, the Netherlands Cancer Institute, University of Twente and industry partners, Lightpoint Medical and Philips will evaluate a novel molecular imaging technology to image the prostate cancer biomarker Prostate Specific Membrane Antigen (PSMA) during surgery.

Augmedics, a developer of an augmented-reality (AR) surgical visualization system, has secured $8.3 million in Series A funding. Led by Davos, Switzerland-based AO Invest, which is fully funded by the non-profit AO Foundation, as well as Israeli Innovation Authority, Terra Venture Partners and other undisclosed investors. Augmedics will use the proceeds to complete research and development as well as pre-clinical and clinical trials of its ViZOR System, establish strategic distribution partnerships, and seek 510(k) clearance for The ViZOR from the US. Food and Drug Administration.